Searched for
CADILA MEDICINE BAN
PIL in HC seeks all Remdesivir makers be allowed to sell it in domestic marketThe remaining companies were involved in manufacturing the drug for export, petitioner Dincur Bajaj said, adding that since export of Remde...
Customs duty waive off on Remdesivir will further augment domestic availability: Sadanand Gowda"Considering the immediate requirement on the recommendation of the Department of Pharmaceuticals, the Department of Revenue has reduced cu...
India lifts export ban on Trump-touted drug hydroxychloroquine"Department of Pharmaceuticals has approved the lifting of ban on Export of Hydroxychloroquine API as well as formulations," India's minist...
A moment when India can save lives, we can’t let it go: PM Modi on lifting HCQ banPrime Minister Narendra Modi insisted that India help out other countries that need hydroxycholoroquine rather than opting for a blanket ex...
Enough stock of hydroxychloroquine in India: Govt"There is enough stock of hydroxychloroquine in the country and we are tracking its demand, availability and production on a daily basis," ...
India to export hydroxychloroquine only to foreign governments and not to private companies: Sources"Hydroxychloroquine continues to be a prohibited item. Private-to-private company or a domestic exporter-to-foreign importer trade is ban. ...
Like Torrent, Cadila, Dr Reddy’s in pharma space: Prakash AgarwalPrefer pharma names with high earnings visibility, says Deputy Head of Research at Axis Capital.
A $300-billion reason India's drug price cap will stayWhen it comes to intellectual property, it's now understood — and grudgingly accepted — that India's use of compulsory licensing won't go a...
Market Now: Pharma index lone loser among sectoral indicesIn the Nifty50 pack, 27 stocks were trading in green, while 24 stocks were in red.
- Buy Cadila Healthcare Ltd., target Rs 440.0 : Citigroup
Citigroup sees limited scope for further deterioration in Cadilla Healthcare financials.
Most pharma companies earn USFDA wrath over data integrity issuesThe US is the largest market for domestic generic companies, contributing 25-55% of revenues for large companies, while India supplies arou...
Zoher Sihorwala to head Wockhardt's regulatory unitMumbai-based pharmaceutical company Wockhardt has appointed Zoher Sihorwala to head its regulatory and compliance division, a senior execut...
IPA hits out at ban on anti-diabetes drug PioglitazoneIndian Pharmaceutical Alliance hit out at the Union Health Ministry's ban on anti-diabetes drug Pioglitazone saying it was done "without fo...
Health ministry bans two drugs Analgin and Pioglitazone; industry protestsThe health ministry has suspended the sale of two drugs - painkiller Analgin and anti-diabetes drug Pioglitazone and all its combinations.
- USFDA lifts sales ban as Indian drug companies take corrective actions
Companies which have taken corrective action after being penalised for violating FDA norms have been allowed to resume sales.
- USFDA to inspect facilities of Zydus, Claris Lifesciences for violating American drug manufacturing norms
FDA had issued warning letter for Cadila's injectable unit at its plant in July for not meeting US drug manufacturing norms .
- USFDA bans sale of medicines from DRL's Mexico facility, warns Cadila
The USFDA on Wednesday banned the US sale of medicines made at Dr Reddy's Mexican facility and sent a warning to letter Cadila Healthcare f...